AR054830A1 - Derivados de indol -3-il-espiro-piperidina como antagonista del receptor v1a - Google Patents
Derivados de indol -3-il-espiro-piperidina como antagonista del receptor v1aInfo
- Publication number
- AR054830A1 AR054830A1 ARP060102988A ARP060102988A AR054830A1 AR 054830 A1 AR054830 A1 AR 054830A1 AR P060102988 A ARP060102988 A AR P060102988A AR P060102988 A ARP060102988 A AR P060102988A AR 054830 A1 AR054830 A1 AR 054830A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- optionally substituted
- halogen
- nririi
- aryl
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 24
- 229910052736 halogen Inorganic materials 0.000 abstract 10
- 150000002367 halogens Chemical class 0.000 abstract 10
- 125000003118 aryl group Chemical group 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 2
- 125000001041 indolyl group Chemical group 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- -1 -O-CH2-C2-6 alkenyl Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicacion 1: Compuestos de la formula general (1), en la que: A se elige entre los grupos de formulas (2) a (9) en los que, en la formula (2) la línea de puntos es nula o es un doble enlace; R1 es H; o es alquilo C1-6 opcionalmente sustituido por CN; o es arilo, heteroarilo o sulfonilarilo de 5 o 6 eslabones, que están opcionalmente sustituidos por uno o varios B; o es -(CH2)m-Ra, en el que R4 es: CN; ORi; NRiRii; cicloalquilo C3-6, heterocicloalquilo de 3 a 7 eslabones, arilo, o heteroarilo de 5 o 6 eslabones, que están opcionalmente sustituidos por uno o varios B; o es -(CH2)n-C(O)-Rb o -(CH2)n-(SO2)-Rb, en el que Rb es: alquilo C1-6; alcoxi C1-6; cicloalquilo C3-6; -(CH2)m-RiiiRiv; NRiRii; cicloalquilo C3-6, heterocicloalquilo de 4 a 7 eslabones, arilo, o heteroarilo de 5 o 6 eslabones, que están opcionalmente sustituidos por uno o varios B; o R1 y R3 junto con el anillo indol al que están unidos forman un heterocicloalquilo de 5 o 6 eslabones, que puede estar sustituido por =O, C(O)O-alquiloC1-6 o alquilo C1-6; R2 es uno o varios de H, OH, halogeno, CN, nitro, alquilo C1-6 opcionalmente sustituido por -NRiiiRiv, alcoxi C1-6, -O-CH2-alqueniloC2-6, benciloxi; o dos R2 pueden formar un puente oxo o dioxo junto con el anillo indol, al que están unidos; R3 es H; o es halogeno; o es -(CO)-Rc, en el que Rc es: alquilo C1-6; -(CH2)n-NRiRii; -(CH2)n-NRiiiRiv; heterocicloalquilo de 5 o 6 eslabones, opcionalmente sustituido por alquilo C1-6; o es alquilo C1-6 o arilo, que están opcionalmente sustituido por: halogeno; -O(CO)-alquiloC1-6; o por -NH(CO)Rd, en el que Rd es alquilo C1-6 opcionalmente sustituido por halogeno o nitro, o Rd es arilo o un heteroarilo de 5 o 6 eslabones, que están opcionalmente sustituidos por halogeno, nitro, alquilo C1-6 o haloalquilo C1-6; R4 es uno o varios de H; halogeno, alquilo C1-6 o alcoxi C1-6 opcionalmente sustituido por OH, o dos R4 pueden formar un puente oxo o dioxo junto con el anillo fenilo, al que están unidos; R5 es H, alquilo C1-6 o arilo; R6 es H o alquilo C1-6; R7 es H o -SO2-Re en el que Re es alquilo C1-6 o arilo; R8 es H o alquilo C1-6; X es CH2 o C=O; B es halogeno, CN, NRiRii, alquilo C1-6 opcionalmente sustituido por CN, halogeno, o alcoxi C1-6, alcoxi C1-6, haloalcoxi C1-6, cicloalquilo C3-6, -C(O)O-alquiloC1-6, -C(O)-NRiRii, -C(O)-alquiloC1-6, -S(O)2-alquiloC1-6, -S(O)2-NRiRii, (CRiiiRiv)n-fenilo, o (CRiiiRiv)n-heteroarilo de 5 o 6 eslabones, en el que el resto fenilo o heteroarilo de 5 o 6 eslabones está opcionalmente sustituido por uno o varios sustituyentes elegidos entre el grupo formado por: halogeno, CN, NRiRii, alquilo C1-6 opcionalmente sustituido por CN, halogeno o alcoxi C1-6, alcoxi C1-6, haloalcoxi C1-6, cicloalquilo C3-6, -C(O)O-alquiloC1-6, -C(O)-NRiRii, -C(O)-alquiloC1-6, -S(O)2-alquiloC1-6, -S(O)2-NRiRii; Ri y Rii son H, alquilo C1-6, alquiloC1-6-NRiiiRiv, -(CO)O-alquiloC1-6, -C(O)-NRiiiRiv, -C(O)-alquiloC1-6, -S(O)2-alquiloC1- 6, -S(O)2-NRiiiRiv u OH; Riii y Riv son H o alquilo C1-6; m es un numero de 1 a 6; n es un numero de 0 a 4; así como a las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05106443 | 2005-07-14 | ||
| EP05109364 | 2005-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054830A1 true AR054830A1 (es) | 2007-07-18 |
Family
ID=37001896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102988A AR054830A1 (es) | 2005-07-14 | 2006-07-12 | Derivados de indol -3-il-espiro-piperidina como antagonista del receptor v1a |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7332501B2 (es) |
| EP (1) | EP1904477B1 (es) |
| JP (1) | JP4927079B2 (es) |
| KR (1) | KR100974967B1 (es) |
| CN (1) | CN101253164B (es) |
| AR (1) | AR054830A1 (es) |
| AT (1) | ATE421511T1 (es) |
| AU (1) | AU2006268724B2 (es) |
| BR (1) | BRPI0612988A2 (es) |
| CA (1) | CA2615726C (es) |
| CY (1) | CY1108996T1 (es) |
| DE (1) | DE602006004997D1 (es) |
| DK (1) | DK1904477T3 (es) |
| ES (1) | ES2317558T3 (es) |
| IL (1) | IL188478A (es) |
| MX (1) | MX2008000585A (es) |
| MY (1) | MY144684A (es) |
| NO (1) | NO20080059L (es) |
| PL (1) | PL1904477T3 (es) |
| PT (1) | PT1904477E (es) |
| RU (1) | RU2414466C2 (es) |
| SI (1) | SI1904477T1 (es) |
| TW (1) | TWI312780B (es) |
| WO (1) | WO2007006688A1 (es) |
| ZA (1) | ZA200800320B (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1904477T3 (pl) * | 2005-07-14 | 2009-07-31 | Hoffmann La Roche | Pochodne indolo-3-karbonylo-spiro-piperydyny jako antagoniści receptora V1a |
| ATE488519T1 (de) * | 2005-09-28 | 2010-12-15 | Hoffmann La Roche | Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten |
| US7351706B2 (en) * | 2006-01-05 | 2008-04-01 | Hoffmann-La Roche Inc. | Indol-3-yl-carbonyl-spiro-piperidine derivatives |
| WO2008068185A1 (en) | 2006-12-07 | 2008-06-12 | F. Hoffmann-La Roche Ag | Spiro-piperidine derivatives as via receptor antagonists |
| CN101541786A (zh) | 2006-12-08 | 2009-09-23 | 弗·哈夫曼-拉罗切有限公司 | 作为V1a受体拮抗剂的吲哚类化合物 |
| KR20090082502A (ko) * | 2006-12-22 | 2009-07-30 | 에프. 호프만-라 로슈 아게 | 스피로-피페리딘 유도체 |
| ES2376378T3 (es) * | 2007-01-12 | 2012-03-13 | F. Hoffmann-La Roche Ag | Derivados de espiropiperidina-glicinamida. |
| TW200940547A (en) * | 2007-12-13 | 2009-10-01 | Speedel Experimenta Ag | Organic compounds |
| WO2011137024A1 (en) * | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| PT2683723T (pt) | 2011-03-10 | 2016-08-05 | Zoetis Services Llc | Derivados espirocíclicos de isoxazolina como agentes antiparasitários |
| RU2475489C1 (ru) * | 2011-10-07 | 2013-02-20 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Чувашский государственный университет имени И.Н. Ульянова" | Способ получения 8-амино-1-имино-6-морфолин-4-ил-2-окса-7-азаспиро[4,4]нона-3,6,8-триен-9-карбонитрилов |
| CN104203950B (zh) | 2012-03-16 | 2016-08-24 | 生命医药公司 | 肝x受体调节剂 |
| HUE029402T2 (en) | 2012-03-16 | 2017-02-28 | Vitae Pharmaceuticals Inc | Liver X receptor modulators |
| JO3109B1 (ar) * | 2012-05-10 | 2017-09-20 | Ferring Bv | منبهات لمستقبلات v1a |
| KR101698124B1 (ko) * | 2015-05-29 | 2017-01-19 | 한국외국어대학교 연구산학협력단 | 3-(메틸아미노)-3-((r)-피롤리딘-3-일)프로판니트릴 또는 이의 염의 제조방법 |
| WO2017137334A1 (en) * | 2016-02-08 | 2017-08-17 | F. Hoffmann-La Roche Ag | Spiroindolinones as ddr1 inhibitors |
| US20180002344A1 (en) | 2016-06-16 | 2018-01-04 | Genentech, Inc. | Heteroaryl estrogen receptor modulators and uses thereof |
| CA3037222C (en) | 2016-09-21 | 2024-02-13 | Vectus Biosystems Limited | Compositions for the treatment of hypertension and/or fibrosis |
| HU231206B1 (hu) | 2017-12-15 | 2021-10-28 | Richter Gedeon Nyrt. | Triazolobenzazepinek |
| TW201938171A (zh) | 2017-12-15 | 2019-10-01 | 匈牙利商羅特格登公司 | 作為血管升壓素Ｖ１ａ受體拮抗劑之三環化合物 |
| CN113563255B (zh) * | 2020-04-29 | 2023-08-18 | 成都倍特药业股份有限公司 | 瑞芬沙星中间体的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5686624A (en) * | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| RO115804B1 (ro) * | 1992-12-11 | 2000-06-30 | Merck & Co Inc | Derivati de spiropiperidine, procedee de preparare si compozitii farmaceutice ale acestora |
| EP1410437A2 (en) * | 2001-01-22 | 2004-04-21 | Morgan Chemical Products, Inc. | Cvd diamond enhanced microprocessor cooling system |
| PL1904477T3 (pl) * | 2005-07-14 | 2009-07-31 | Hoffmann La Roche | Pochodne indolo-3-karbonylo-spiro-piperydyny jako antagoniści receptora V1a |
-
2006
- 2006-07-04 PL PL06764048T patent/PL1904477T3/pl unknown
- 2006-07-04 RU RU2008100082/04A patent/RU2414466C2/ru not_active IP Right Cessation
- 2006-07-04 MX MX2008000585A patent/MX2008000585A/es active IP Right Grant
- 2006-07-04 DK DK06764048T patent/DK1904477T3/da active
- 2006-07-04 CA CA2615726A patent/CA2615726C/en not_active Expired - Fee Related
- 2006-07-04 PT PT06764048T patent/PT1904477E/pt unknown
- 2006-07-04 CN CN2006800321491A patent/CN101253164B/zh not_active Expired - Fee Related
- 2006-07-04 ES ES06764048T patent/ES2317558T3/es active Active
- 2006-07-04 WO PCT/EP2006/063846 patent/WO2007006688A1/en not_active Ceased
- 2006-07-04 JP JP2008520842A patent/JP4927079B2/ja not_active Expired - Fee Related
- 2006-07-04 AU AU2006268724A patent/AU2006268724B2/en not_active Ceased
- 2006-07-04 AT AT06764048T patent/ATE421511T1/de active
- 2006-07-04 SI SI200630231T patent/SI1904477T1/sl unknown
- 2006-07-04 KR KR1020087002692A patent/KR100974967B1/ko not_active Expired - Fee Related
- 2006-07-04 EP EP06764048A patent/EP1904477B1/en not_active Not-in-force
- 2006-07-04 BR BRPI0612988-9A patent/BRPI0612988A2/pt not_active IP Right Cessation
- 2006-07-04 DE DE602006004997T patent/DE602006004997D1/de active Active
- 2006-07-10 US US11/483,462 patent/US7332501B2/en not_active Expired - Fee Related
- 2006-07-10 TW TW095125012A patent/TWI312780B/zh not_active IP Right Cessation
- 2006-07-11 MY MYPI20063280A patent/MY144684A/en unknown
- 2006-07-12 AR ARP060102988A patent/AR054830A1/es not_active Application Discontinuation
-
2007
- 2007-12-27 IL IL188478A patent/IL188478A/en not_active IP Right Cessation
-
2008
- 2008-01-04 NO NO20080059A patent/NO20080059L/no not_active Application Discontinuation
- 2008-01-10 ZA ZA200800320A patent/ZA200800320B/xx unknown
- 2008-01-24 US US12/018,823 patent/US7629353B2/en not_active Expired - Fee Related
-
2009
- 2009-04-14 CY CY20091100447T patent/CY1108996T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054830A1 (es) | Derivados de indol -3-il-espiro-piperidina como antagonista del receptor v1a | |
| PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
| AR025386A1 (es) | Moduladores de los receptores activados del proliferador de peroxisomas | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR074648A1 (es) | Derivados de isoxazolina que poseen un anillo de cuatro miembros como grupo terminal, intermediarios de sintesis, composiciones biocidas que los contienen y metodos para combatir y controlar dichas plagas | |
| AR043059A1 (es) | Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR047056A1 (es) | Derivados de pirimidinas condensadas. composiciones farmacéuticas | |
| AR059136A1 (es) | Derivados de indol-3-il-carbonil-espiro-piperidina | |
| CO4970713A1 (es) | Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen | |
| AR044614A1 (es) | Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4) | |
| AR070992A1 (es) | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 | |
| AR057086A1 (es) | Derivados de indol-3- il-carbonil-piperidina y piperazina, composicion farmaceutica y proceso de preparacion del compuesto | |
| AR037816A1 (es) | Fenil derivados sustituidos | |
| CO6160312A2 (es) | Derivados de quiniclidina de acido (hetero) arilcicloheptano carboxilico como antagonistas del receptor muscarinico | |
| CO6180439A2 (es) | Derivados de quinuclidinol como antagonistas de receptores muscarinicos | |
| AR074862A1 (es) | Derivados de heterociclo biciclicos y sus metodos de uso | |
| CR9959A (es) | Derivados de pirazol | |
| AR052568A1 (es) | Derivados de pirazolo -pirimidina como antagonstas de mglur2 | |
| AR062294A1 (es) | Derivados de 5,6 -bisaril-2-piridin-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de urotensina ii | |
| AR052419A1 (es) | Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit | |
| AR069814A1 (es) | Derivados de 4 amino-pirimidina, proceso de preparacion y composiciones farmaceuticas que los contienen | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| AR045859A1 (es) | Derivados de dibenzoazepina y de benzodiazepinas sustitudos, procesos de preparacion y usos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |